Prothena (PRTA) Competitors

Denali Therapeutics (NASDAQ:DNLI) and Prothena (NASDAQ:PRTA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.

Which has more risk and volatility, DNLI or PRTA?

Denali Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500.

Which has preferable valuation & earnings, DNLI or PRTA?

Denali Therapeutics has higher revenue and earnings than Prothena. Denali Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.04	-$145.22M	-$2.76	-7.52
Prothena	$91.37M	9.16	-$147.03M	-$2.48	-6.27

Does the media prefer DNLI or PRTA?

In the previous week, Prothena had 17 more articles in the media than Denali Therapeutics. MarketBeat recorded 20 mentions for Prothena and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.65 beat Prothena's score of 0.13 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	3 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor DNLI or PRTA?

Prothena received 152 more outperform votes than Denali Therapeutics when rated by MarketBeat users. Likewise, 70.47% of users gave Prothena an outperform vote while only 68.20% of users gave Denali Therapeutics an outperform vote.

Company	Underperform	Outperform
Denali Therapeutics	Outperform Votes 459 68.20%	Underperform Votes 214 31.80%
Prothena	Outperform Votes 611 70.47%	Underperform Votes 256 29.53%

Do insiders and institutionals have more ownership in DNLI or PRTA?

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Comparatively, 28.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is DNLI or PRTA more profitable?

Denali Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -98.86%. Prothena's return on equity of -24.19% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-32.94%	-30.04%
Prothena	-98.86%	-24.19%	-20.59%

Do analysts prefer DNLI or PRTA?

Denali Therapeutics currently has a consensus target price of $37.42, suggesting a potential upside of 80.29%. Prothena has a consensus target price of $45.83, suggesting a potential upside of 194.56%. Given Prothena's higher probable upside, analysts clearly believe Prothena is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Prothena	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Prothena beats Denali Therapeutics on 11 of the 19 factors compared between the two stocks.